A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies
- PMID: 34607018
- DOI: 10.1016/j.drudis.2021.09.009
A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies
Abstract
Drug labeling informs physicians and patients on the safe and effective use of medication. However, recent studies suggested discrepancies in labeling of the same drug between different regulatory agencies. Here, we evaluated the hepatic safety information in labeling for 549 medications approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Limited discrepancies were found regarding risk for hepatic adverse drug reactions (ADRs) (8.7% in hepatic ADR warnings and 21.3% in contraindication for liver disease), while caution should be exercised over drugs with inconsistencies in contraindications for liver disease and evidence for hepatotoxicity (4.9%). Most discrepancies were attributable to less-severe hepatic events and low-frequency hepatic ADR reports and had limited implication on clinical outcomes.
Keywords: Adverse drug reactions; Contraindication; Drug labeling; Drug-induced liver injury; EMA; FDA; LiverTox; Warnings and precautions.
Published by Elsevier Ltd.
Conflict of interest statement
Competing interests The authors have no conflicts to disclose.
Similar articles
-
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6. Milbank Q. 2020. PMID: 33021339 Free PMC article.
-
A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).Value Health. 2019 Feb;22(2):203-209. doi: 10.1016/j.jval.2018.09.2842. Value Health. 2019. PMID: 30711065 Review.
-
Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).Value Health. 2013 Dec;16(8):1150-5. doi: 10.1016/j.jval.2013.08.2293. Epub 2013 Oct 17. Value Health. 2013. PMID: 24326168
-
A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.Eur J Clin Pharmacol. 2018 Jun;74(6):811-818. doi: 10.1007/s00228-018-2431-7. Epub 2018 Feb 22. Eur J Clin Pharmacol. 2018. PMID: 29470610
-
Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.Drug Metab Dispos. 2022 Jun;50(6):879-887. doi: 10.1124/dmd.121.000418. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221289 Free PMC article. Review.
Cited by
-
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency.Pharmacol Res Perspect. 2023 Apr;11(2):e01067. doi: 10.1002/prp2.1067. Pharmacol Res Perspect. 2023. PMID: 36846954 Free PMC article.
-
Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure.Sci Rep. 2024 Apr 20;14(1):9074. doi: 10.1038/s41598-024-59710-3. Sci Rep. 2024. PMID: 38643204 Free PMC article.
-
Computational models for predicting liver toxicity in the deep learning era.Front Toxicol. 2024 Jan 19;5:1340860. doi: 10.3389/ftox.2023.1340860. eCollection 2023. Front Toxicol. 2024. PMID: 38312894 Free PMC article. Review.
-
Oral Drugs Against COVID-19.Dtsch Arztebl Int. 2022 Apr 15;119(15):263-269. doi: 10.3238/arztebl.m2022.0152. Dtsch Arztebl Int. 2022. PMID: 35302484 Free PMC article.
-
Automatic text classification of drug-induced liver injury using document-term matrix and XGBoost.Front Artif Intell. 2024 Jun 3;7:1401810. doi: 10.3389/frai.2024.1401810. eCollection 2024. Front Artif Intell. 2024. PMID: 38887604 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
